Biocept, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was USD 36.14 million compared to USD 47.27 million a year ago. Net loss was USD 13.57 million compared to net income of USD 0.147 million a year ago. Basic loss per share from continuing operations was USD 24 compared to basic earnings per share from continuing operations of USD 0.3 a year ago. Diluted loss per share from continuing operations was USD 24 compared to diluted earnings per share from continuing operations of USD 0.3 a year ago.